Annual report pursuant to Section 13 and 15(d)
Cover
Document and Entity Information
Financial Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements of Operations
Consolidated Statement of Changes in Stockholders' Equity (Deficit)
Consolidated Statements of Cash Flows
Notes to Financial Statements
Description of Business and Summary of Significant Accounting Policies
Related Party Transactions
Property and Equipment
Note Payable and Convertible Notes
Derivatives
Income Taxes
Commitments and Contingencies
Equity
Employee Defined Contribution Plan
Subsequent Events
Accounting Policies
Description of Business and Summary of Significant Accounting Policies (Policies)
Notes Tables
Description of Business and Summary of Significant Accounting Policies (Tables)
Related Party Transactions (Tables)
Property and Equipment (Tables)
Derivatives (Tables)
Income Taxes (Tables)
Commitments and Contingencies (Tables)
Equity (Tables)
Notes Details
Description of Business and Summary of Significant Accounting Policies (Details)
Description of Business and Summary of Significant Accounting Policies (Details Textual)
Related Party Transactions (Details)
Related Party Transactions (Details Textual)
Property and Equipment (Details)
Property and Equipment (Details Textual)
Note Payable and Convertible Notes (Details Textual)
Derivatives (Details)
Derivatives (Details 1)
Derivatives (Details Textual)
Income Taxes (Details)
Income Taxes (Details 1)
Income Taxes (Details Textual)
Commitments and Contingencies (Details)
Commitments and Contingencies (Details Textual)
Commitments and Contingencies (Details Textual 1)
Equity (Details)
Equity (Details 1)
Equity (Details Textual)
Employee Defined Contribution Plan (Details)
Subsequent Events (Details)
Commitments and Contingencies (Tables)
v2.4.0.8
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2013
Milestone Payments Milestone Method [Line Items]
Summary of milestone payment
Milestones
Payments
(1) when Company initiates a Phase 1 Clinical Trial of a licensed product
$
750,000
(2) when Company initiates a Phase 2 Clinical Trial of a licensed product
750,000
(3) when Company initiates a Phase 3 Clinical Trial of a licensed product
1,500,000
(4) Biological License Application filing with U.S. FDA
1,750,000
(5) First commercial sale
1,500,000
(6) after the first $10,000,000 in net sales
1,500,000
X
- Details
Name:
atnm_MilestonePaymentsMilestoneMethodLineItems
Namespace Prefix:
atnm_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Milestone payments milestone method.
+ References
No definition available.
+ Details
Name:
atnm_MilestonePaymentsMilestoneMethodTableTextBlock
Namespace Prefix:
atnm_
Data Type:
nonnum:textBlockItemType
Balance Type:
na
Period Type:
duration